Policy & Regulation
WuXi LabNetwork, Science Exchange Forge Technology Partnership to Allow Rapid Access to Reagents e-Catalog
22 March 2019 - - US-based R and D services management company Science Exchange and China-based chemistry e-commerce platform WuXi LabNetwork have forged a technology partnership that will allow Scien...
Sanofi Starts Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis, Triggering Milestone Payment to Lead Pharma
22 March 2019 - - Dutch pharmaceutical company Lead Pharma has achieved a fourth milestone under its license and collaboration agreement with French drugmaker Sanofi (NYSE: SNY), triggering an undiscl...
Samsung Bioepis Releases Three-year Follow-up Data for Biosimilar Ontruzant in Early or Locally Advanced HER2-positive Breast Cancer
22 March 2019 - - South Korea-based Samsung Bioepis Co., Ltd has received findings of a three-year follow-up study comparing biosimilar Ontruzant (trastuzumab) and reference medicine trastuzumab in ea...
Oragenics Prices USD 12.5m Underwritten Public Offering
22 March 2019 - - US-based antibiotics developer Oragenics, Inc. (NYSE American: OGEN) has priced an underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase ...
Imago BioSciences Raises USD 40m Series B Financing Led by Omega Funds
22 March 2019 - - US-based clinical-stage biotechnology company Imago BioSciences, Inc has secured USD 40m series B financing led by Omega Funds, a international investment firm that creates and inves...
Abzena Launches New Fully Integrated Developability and Optimisation Service to Improve Lead Selection and De-risk Biologic Cell Line Development
22 March 2019 - - UK-based early discovery to mid-phase biotherapeutic and ADC drug development services provider Abzena's Cambridge UK site has brought together its extensive discovery, immunoge...
Related Headlines

LegoChem Biosciences partners with Takeda for development of antibody-drug conjugates in immuno-oncology

BioArctic comments on trading halt of its shares by Nasdaq Stockholm on 21 March 2019

Hansa Biopharma selects lead candidate from NiceR programme

Agenus names new strategic advisor and global head of Clinical Operations

Pfizer given exclusive option to acquire Vivet Therapeutics

Merck opts to extend research phase of Merck and NGM Biopharmaceuticals strategic collaboration

First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute

Aura to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting

Transgene Secures a EUR 20m Revolving Credit Facility with Natixis

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer

FDA Approves Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer

Novo Nordisk submits two NDAs to US FDA for oral semaglutide and sNDA for Ozempic

Boehringer Ingelheim Files FDA and EMA Regulatory Submission for Nintedanib in Systemic Sclerosis Associated ILD

Bicycle Therapeutics Names Legault as New Director and Board Chairman

Innovent doses first hypercholesterolemia patient in China in Phase IIa Clinical Study of IBI306